Volume 23, Number 6—June 2017
Research
Distribution and Quantitative Estimates of Variant Creutzfeldt-Jakob Disease Prions in Tissues of Clinical and Asymptomatic Patients
Jean Y. Douet, Caroline Lacroux, Naima Aron, Mark W. Head, Séverine Lugan, Cécile Tillier, Alvina Huor, Hervé Cassard, Mark Arnold, Vincent Beringue, James W. Ironside, and Olivier Andréoletti
Table 3
Characteristics of 5 patients with vCJD and 2 controls in study of distribution and quantitative estimates of variant prions in tissues*
| Patient identification no. | Diagnosis | Sex | Year of death | Age, y, at death | Disease duration, mo | PRNP gene codon 129 | PRNP gene mutations |
|---|---|---|---|---|---|---|---|
| vCJD-1 | vCJD | M | 1999 | 33 | 18 | MM | None detected |
| vCJD-2 | vCJD | F | 2000 | 17 | 18 | MM | None detected |
| vCJD-4 | vCJD | M | 2000 | 26 | 10 | MM | None detected |
| vCJD-3 | vCJD | M | 2001 | 26 | 10 | MM | None detected |
| vCJD-A | Asymptomatic vCJD | F | 2004 | 82 | NA | MV | None detected |
| NC-1 | No CJD (tumor, infarction, ischemia) | F | 2005 | 85 | NA | MM | No consent for sequencing |
| NC-2 | No CJD (Alzheimer’s disease, infarction, ischemia) | F | 2010 | 80 | NA | MM | None detected |
*NA, not applicable; vCJD, variant Creutzfeldt-Jakob disease.
Page created: May 16, 2017
Page updated: May 16, 2017
Page reviewed: May 16, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.